Evidence map›Paper›PMID 36052140›Full record

ArticleFrontiers in pharmacology2022

Effects of 3,4-diaminopyridine on myasthenia gravis: Preliminary results of an open-label study.

Marco Ceccanti, Laura Libonati, Gabriele Ruffolo, Pierangelo Cifelli, Federica Moret, Vittorio Frasca, Eleonora Palma, Maurizio Inghilleri, Chiara Cambieri

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Marco CeccantiNeuromuscular Disorders Unit, Department of Human Neurosciences, Sapienza University, Rome, Italy.
Laura LibonatiNeuromuscular Disorders Unit, Department of Human Neurosciences, Sapienza University, Rome, Italy.
Gabriele RuffoloDepartment of Physiology and Pharmacology, Institute Pasteur- Fondazione Cenci Bolognetti, University of Rome Sapienza, Rome, Italy.
Pierangelo CifelliDepartment of Applied Clinical and Biotechnological Sciences, University of L'Aquila, L'Aquila, Italy.
Federica MoretNeuromuscular Disorders Unit, Department of Human Neurosciences, Sapienza University, Rome, Italy.
Vittorio FrascaNeuromuscular Disorders Unit, Department of Human Neurosciences, Sapienza University, Rome, Italy.
Eleonora PalmaDepartment of Physiology and Pharmacology, Institute Pasteur- Fondazione Cenci Bolognetti, University of Rome Sapienza, Rome, Italy.
Maurizio InghilleriNeuromuscular Disorders Unit, Department of Human Neurosciences, Sapienza University, Rome, Italy.
Chiara CambieriNeuromuscular Disorders Unit, Department of Human Neurosciences, Sapienza University, Rome, Italy.
Sapienza University of Rome · ITIstituto Pasteur · ITUniversity of L'Aquila · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

3,4-diaminopyridine (3,4-DAP)acetylcholine receptorsanti-AChR antibodiesmyasthenia gravisquantitative myasthenia gravis testrepetitive nerve stimulation

Identifiers

PMID36052140
PMCPMC9424766
OpenAlexW4291939014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.